Andrew Lo insider trades: BridgeBio Pharma (BBIO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
and 1 more company
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | BBIO | ↓ Sell | 55,000 | $65.69 | $3.6M | By Andrew W. Lo and Nancy N. Lo JTWROS | Nov 19, 2025 (1d) |
| Nov 17, 2025 | BBIO | ↓ Sell | 40,599 | $66.67 | $2.7M | Direct | Nov 19, 2025 (2d) |
| May 2, 2025 | BBIO | ↓ Sell | 100,000 | $38.50 | $3.8M | By Andrew W. Lo and Nancy N. Lo JTWROS | May 6, 2025 (4d) |
| Dec 30, 2021 | BBIO | ↑ Buy | 7,500 | $13.18 | $99K | Direct | Jan 3, 2022 (4d) |
| Dec 3, 2021 | ABCL | ↑ Buy | 86,938 | $14.02 | $1.2M | Direct | Dec 7, 2021 (4d) |
| Jun 19, 2019 | UROV | ↑ Buy10b5-1 | 18,204 | $8.32 | $151K | Indirect | Jun 19, 2019 (0d) |
| Jun 14, 2019 | UROV | ↑ Buy | 22,011 | $8.06 | $177K | Indirect | Jun 14, 2019 (0d) |
| Jun 11, 2019 | UROV | ↑ Buy10b5-1 | 21,338 | $8.31 | $177K | Indirect | Jun 11, 2019 (0d) |
| Jun 6, 2019 | UROV | ↑ Buy10b5-1 | 21,122 | $7.86 | $166K | Indirect | Jun 6, 2019 (0d) |
| Jun 4, 2019 | MYOV | ↑ Buy | 2,424,242 | $8.25 | $20.0M | Indirect | Jun 6, 2019 (2d) |
| Jun 3, 2019 | UROV | ↑ Buy10b5-1 | 17,746 | $7.83 | $139K | Indirect | Jun 3, 2019 (0d) |
| May 29, 2019 | UROV | ↑ Buy10b5-1 | 14,485 | $7.63 | $110K | Indirect | May 29, 2019 (0d) |
| May 23, 2019 | UROV | ↑ Buy | 19,830 | $8.22 | $163K | Indirect | May 23, 2019 (0d) |
| May 20, 2019 | UROV | ↑ Buy | 21,608 | $7.54 | $163K | Indirect | May 20, 2019 (0d) |
| Mar 18, 2019 | AXON | ↑ Buy | 6,666,667 | $1.50 | $10.0M | Indirect | Mar 19, 2019 (1d) |
| Dec 18, 2018 | AXON | ↑ Buy | 10,000,000 | $1.00 | $10.0M | Indirect | Dec 20, 2018 (2d) |
| Oct 1, 2018 | UROV | ↑ Buy | 2,678,571 | $14.00 | $37.5M | Indirect | Oct 3, 2018 (2d) |
| Jun 5, 2018 | AXON | ↑ Buy | 14,285,714 | $1.75 | $25.0M | Indirect | Jun 7, 2018 (2d) |
| Apr 2, 2018 | MYOV | ↑ Buy | 1,110,015 | $20.27 | $22.5M | Indirect | Apr 4, 2018 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BBIO insiders
Open-market trades in the last 12 months
About Andrew Lo's insider trades
Andrew Lo is a director at BridgeBio Pharma (BBIO). Since Apr 2, 2018, Andrew has reported 16 open-market purchases worth $127.6M and 3 sales worth $10.2M on SEC Form 4. In the last 12 months: 2 sales ($6.3M).
Their filings also include grants and awards (11 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.